-
公开(公告)号：US20100305179A1
公开(公告)日：2010-12-02
申请号：US12855226
申请日：2010-08-12
IPC分类号： A61K31/4174 , A61P13/00
CPC分类号： A61K9/2054 , A61K31/4174
摘要： (Object) An oral sustained-release tablet is provided, which does not cause initial rapid increases in the bloodlevels of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (KRP-197) and can maintain constant the blood levels.(Solving means) An oral sustained-release tablet comprises a pharmaceutical composition and a gel-forming material, the pharmaceutical composition containing KRP-197 as an active ingredient.
摘要翻译： （对象）提供口服持续释放片剂，其不会引起4-（2-甲基-1-咪唑基）-2,2-二苯基丁基酰胺（KRP-197）的血液水平的初始快速增加，并且可以保持恒定 血液水平。 （解决方案）口服缓释片剂包含药物组合物和凝胶形成材料，所述药物组合物含有KRP-197作为活性成分。
-
公开(公告)号：US06446715B2
公开(公告)日：2002-09-10
申请号：US09748015
申请日：2000-12-27
IPC分类号： F28F312
CPC分类号： F28D1/0316 , F28F3/04
摘要： A flat heat exchange tube comprises an upper wall, a lower wall, right and left side walls interconnecting right and left side edges of the upper and lower walls, and a plurality of reinforcing walls connected between the upper and lower walls, extending longitudinally of the tube and spaced apart from one another. The tube has parallel fluid passages formed inside thereof and extending forward or rearward. Each of the reinforcing walls has a plurality of communication holes arranged at a spacing longitudinally thereof for holding the parallel fluid passages in communication with one another therethrough. The upper surface of the lower wall is provided at a portion thereof forming each of the fluid passages with a plurality of turbulence producing portions extending over the entire width of the fluid passage and arranged at a spacing longitudinally of the passage.
摘要翻译： 扁平的热交换管包括上壁，下壁，互连上壁和下壁的左右侧边缘的左右侧壁，以及连接在上壁和下壁之间的多个加强壁， 并彼此间隔开。 管具有在其内部形成并且向前或向后延伸的平行流体通道。 每个加强壁具有多个沿其长度方向布置的连通孔，用于保持彼此连通的平行流体通道。 下壁的上表面在其形成每个流体通道的部分处设置有多个湍流产生部分，其在流体通道的整个宽度上延伸并且沿通道的纵向布置。
-
公开(公告)号：US20070154543A1
公开(公告)日：2007-07-05
申请号：US10552889
申请日：2004-04-14
IPC分类号： A61K31/325 , A61K31/27 , A61K9/20
CPC分类号： A61K31/195 , A61K9/2866
摘要： Upon performing the clinical study of (S)-2-[3-[N-[4-(4-fluorophenoxy)benzyl]carbamoyl]-4-methoxybenz yl]butanoic acid (hereinafter abbreviated as KRP-101), of which improvement in the lipidmetabolism is expected in a microdose, no oral solid dosage form that allows KRP-101 to be administered quantitatively has been embodied. After mixing KRP-101 with additives (excipient, disintegrator and lubricant), the mixture is granulated, pressed into tablets and coated with coating agent, thereby film-coated tablets uniformly containing a small amount of KRP-101 are obtained, making it possible to administer amicrodose of KRP-101 quantitatively on clinical study.
摘要翻译： 在进行（S）-2- [3- [N- [4-（4-氟苯氧基）苄基]氨基甲酰基] -4-甲氧基苄基]丁酸（以下简称为KRP-101）的临床研究中， 在微剂量中预期脂代谢，已经体现了允许定量施用KRP-101的口服固体剂型。 将KRP-101与添加剂（赋形剂，崩解剂和润滑剂）混合后，将混合物造粒，压制成片剂并用包衣剂涂布，得到均匀含有少量KRP-101的薄膜包衣片剂， 在临床研究中定量地施用KRP-101的微量。
-
公开(公告)号：US20070092566A1
公开(公告)日：2007-04-26
申请号：US10566503
申请日：2004-08-03
IPC分类号： A61K31/4172 , A61K9/22
CPC分类号： A61K9/2054 , A61K31/4174
摘要： An oral sustained-release tablet is provided, which does not cause initial rapid increases in the bloodlevels of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (KRP-197) and can maintain constant the blood levels. (Solving means) An oral sustained-release tablet comprises a pharmaceutical composition and a gel-forming material, the pharmaceutical composition containing KRP-197 as an active ingredient.
摘要翻译： 提供口服持续释放片剂，其不引起4-（2-甲基-1-咪唑基）-2,2-二苯基丁基酰胺（KRP-197）的血液水平的初步快速增加，并且可以保持血液水平恒定。 （解决方案）口服缓释片剂包含药物组合物和凝胶形成材料，所述药物组合物含有KRP-197作为活性成分。
-
公开(公告)号：US08343544B2
公开(公告)日：2013-01-01
申请号：US12855226
申请日：2010-08-12
IPC分类号： A61K9/22
CPC分类号： A61K9/2054 , A61K31/4174
摘要： (Object) An oral sustained-release tablet is provided, which does not cause initial rapid increases in the bloodlevels of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (KRP-197) and can maintain constant the blood levels.(Solving means) An oral sustained-release tablet comprises a pharmaceutical composition and a gel-forming material, the pharmaceutical composition containing KRP-197 as an active ingredient.
摘要翻译： （对象）提供口服持续释放片剂，其不会引起4-（2-甲基-1-咪唑基）-2,2-二苯基丁基酰胺（KRP-197）的血液水平的初始快速增加，并且可以保持恒定 血液水平。 （解决方案）口服缓释片剂包含药物组合物和凝胶形成材料，所述药物组合物含有KRP-197作为活性成分。
-
-
-
-
搜索结果
5 条记录 (耗时 0.008 秒)
